ICML 2023 | Everolimus and itacitinib in patients with HL R/R to brentuximab vedotin and checkpoint inhibitors
Jakub Svoboda
• 16 Jun 2023
Jakub Svoboda, MD, University of Pennsylvania, Philadelphia, PA, shares some insights into a study evaluating the combination of everolimus, an mTOR inhibitor, and itacitinib, an oral JAK inhibitor, in patients with Hodgkin lymphoma (HL) who have failed or are intolerant to brentuximab vedotin (BV) and checkpoint inhibitors. Dr Svoboda first discusses the rationale behind combining these agents, and then summarizes the promising results observed so far. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
